Caribou Biosciences Inc (CRBU)

$1.87 -0.10 (-5.08%)
Market Cap 184.58M
Revenue (ttm) 11.16M
Net Income (ttm) -148.13M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,327.33%
Debt to Equity Ratio 0.00
Volume 958,700
Avg Vol 1,291,258
Day's Range N/A - N/A
Shares Out 96.64M
Stochastic %K 17%
Beta 2.54
Analysts Strong Sell
Price Target $11.33

Company Profile

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 982 6030
Address:
2929 7th Street, Suite 105, Berkeley, United States
NicaInvest85
NicaInvest85 Mar. 19 at 4:51 PM
$CRBU while the stock market is on the decline, oil prices on the rise, and the global economy in uncertainty territory- Biotech, Pharma, and Healthcare can prevail in a downturn.
0 · Reply
HughGeez
HughGeez Mar. 18 at 3:21 AM
$CRBU There is an excellent analysis of CRBU, written by Joseph Minton, published in Seeking Alpha today. It breaks down the positives and negatives of the stock. The article is a great read if you have an interest in this stock.
1 · Reply
josegodoy
josegodoy Mar. 17 at 11:52 PM
$CRBU I’m ready for $2.50–ish
0 · Reply
Peterson28
Peterson28 Mar. 17 at 7:35 PM
$CRBU New thought. It will be acquired by some AI companies instead of big pharma. Acquire the gene editing IP and do some crazy stuff using LLM. Open AI has over $100B looking to deploy for M&A just FYI.
1 · Reply
Midori_Hachi
Midori_Hachi Mar. 15 at 3:49 PM
$CRBU
0 · Reply
RocroBio
RocroBio Mar. 12 at 7:39 PM
$CRBU
0 · Reply
NicaInvest85
NicaInvest85 Mar. 12 at 12:23 PM
$CRBU markets are in descent but healthcare and biotech will sustain. CRBU target price is around $6-$8 for end of year. The evidence looks promising.
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 10 at 9:36 PM
$CRBU Current Stock Price: $2.04 Contracts to trade: $2.0 CRBU Mar 20 2026 Call Entry: $0.05 Exit: $0.10 ROI: 99% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Mindegap
Mindegap Mar. 10 at 4:23 PM
$MGX $PRME $CRBU
0 · Reply
GamblingFerret
GamblingFerret Mar. 10 at 1:41 PM
$CRBU Recording of Leerink is available. https://event.summitcast.com/view/mT9poctHDNthc6b89WqVjf/guest_book?session_id=oDGi666VY8BTVHda7xriwg They are evaluating both dilutive and non dilutive financing options for Phase 3. Final discussions with FDA on Phase 3 trial ongoing. CB11 partnering ready with availibility of longer term data, dose expansion (ongoing) and regulatory exchange with FDA (ongoing). Very interestingly, autoimmune is in high interest as well, potentially with a partner or alone as IND is in place. So CB10 will expand into autoimmune nearterm.
1 · Reply
Latest News on CRBU
Caribou Biosciences: Antlers Up For The Allogenic CAR-T Bet Trading At Cash Value

Mar 17, 2026, 9:38 AM EDT - 4 days ago

Caribou Biosciences: Antlers Up For The Allogenic CAR-T Bet Trading At Cash Value

Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 5, 2026, 4:05 PM EST - 16 days ago

Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing Cost per Sample

Feb 17, 2026, 8:00 AM EST - 4 weeks ago

Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing Cost per Sample

Caribou Biosciences to Participate in Upcoming Investor Conferences

Feb 12, 2026, 4:05 PM EST - 5 weeks ago

Caribou Biosciences to Participate in Upcoming Investor Conferences

Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR®

Feb 4, 2026, 8:00 AM EST - 6 weeks ago

Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR®

Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025

Dec 1, 2025, 4:05 PM EST - 3 months ago

Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025

Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 12, 2025, 4:05 PM EST - 4 months ago

Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update

Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today>

Nov 3, 2025, 11:48 AM EST - 4 months ago

Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today>

Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma

Nov 3, 2025, 7:00 AM EST - 4 months ago

Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma

Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies

Nov 3, 2025, 7:00 AM EST - 4 months ago

Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies

Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma

Nov 2, 2025, 4:00 PM EST - 4 months ago

Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma

Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference

Aug 25, 2025, 4:05 PM EDT - 7 months ago

Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference

Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 12, 2025, 4:05 PM EDT - 7 months ago

Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update

Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference

May 28, 2025, 4:00 PM EDT - 10 months ago

Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference

Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 4:05 PM EDT - 11 months ago

Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update

Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference

May 6, 2025, 4:00 PM EDT - 11 months ago

Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference

Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs

Apr 24, 2025, 4:15 PM EDT - 11 months ago

Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs

Bronstein, Gewirtz & Grossman, LLC Is Investigating Caribou Biosciences, Inc. (CRBU) And Encourages Shareholders to Connect

Apr 10, 2025, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Caribou Biosciences, Inc. (CRBU) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Caribou Biosciences, Inc. (CRBU) And Encourages Shareholders to Reach Out

Apr 8, 2025, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Caribou Biosciences, Inc. (CRBU) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Caribou Biosciences, Inc. (CRBU) and Encourages Shareholders to Learn More About the Investigation

Apr 6, 2025, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Caribou Biosciences, Inc. (CRBU) and Encourages Shareholders to Learn More About the Investigation

Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Apr 3, 2025, 10:00 AM EDT - 1 year ago

Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Apr 1, 2025, 10:00 AM EDT - 1 year ago

Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Caribou Biosciences, Inc. (CRBU) And Encourages Investors to Connect

Mar 30, 2025, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Caribou Biosciences, Inc. (CRBU) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Caribou Biosciences, Inc. (CRBU) Stockholders to Inquire about Securities Investigation

Mar 27, 2025, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Caribou Biosciences, Inc. (CRBU) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Caribou Biosciences, Inc. (CRBU) and Encourages Investors to Learn More About the Investigation

Mar 25, 2025, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Caribou Biosciences, Inc. (CRBU) and Encourages Investors to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Caribou Biosciences, Inc. (CRBU) And Encourages Stockholders to Reach Out

Mar 20, 2025, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Caribou Biosciences, Inc. (CRBU) And Encourages Stockholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Is Investigating Caribou Biosciences, Inc. (CRBU) And Encourages Stockholders to Connect

Mar 18, 2025, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Caribou Biosciences, Inc. (CRBU) And Encourages Stockholders to Connect

Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Mar 16, 2025, 10:00 AM EDT - 1 year ago

Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Caribou Biosciences, Inc. (CRBU) and Encourages Stockholders to Learn More About the Investigation

Mar 13, 2025, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Caribou Biosciences, Inc. (CRBU) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Caribou Biosciences, Inc. (CRBU) Investors to Inquire about Securities Investigation

Mar 11, 2025, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Caribou Biosciences, Inc. (CRBU) Investors to Inquire about Securities Investigation

Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 10, 2025, 4:05 PM EDT - 1 year ago

Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Shareholders of Caribou Biosciences, Inc. Should Contact The Gross Law Firm Before February 24, 2025 to Discuss Your Rights - CRBU

Feb 24, 2025, 5:45 AM EST - 1 year ago

Shareholders of Caribou Biosciences, Inc. Should Contact The Gross Law Firm Before February 24, 2025 to Discuss Your Rights - CRBU

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences

Feb 23, 2025, 9:27 AM EST - 1 year ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of February 24, 2025 in Caribou Biosciences, Inc. Lawsuit – CRBU

Feb 20, 2025, 1:28 PM EST - 1 year ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of February 24, 2025 in Caribou Biosciences, Inc. Lawsuit – CRBU

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences

Feb 19, 2025, 10:22 AM EST - 1 year ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences

CRBU Deadline: Rosen Law Firm Urges Caribou Biosciences, Inc. (NASDAQ: CRBU) Investors to Contact the Firm for Information About Their Rights

Feb 15, 2025, 3:04 PM EST - 1 year ago

CRBU Deadline: Rosen Law Firm Urges Caribou Biosciences, Inc. (NASDAQ: CRBU) Investors to Contact the Firm for Information About Their Rights

NicaInvest85
NicaInvest85 Mar. 19 at 4:51 PM
$CRBU while the stock market is on the decline, oil prices on the rise, and the global economy in uncertainty territory- Biotech, Pharma, and Healthcare can prevail in a downturn.
0 · Reply
HughGeez
HughGeez Mar. 18 at 3:21 AM
$CRBU There is an excellent analysis of CRBU, written by Joseph Minton, published in Seeking Alpha today. It breaks down the positives and negatives of the stock. The article is a great read if you have an interest in this stock.
1 · Reply
josegodoy
josegodoy Mar. 17 at 11:52 PM
$CRBU I’m ready for $2.50–ish
0 · Reply
Peterson28
Peterson28 Mar. 17 at 7:35 PM
$CRBU New thought. It will be acquired by some AI companies instead of big pharma. Acquire the gene editing IP and do some crazy stuff using LLM. Open AI has over $100B looking to deploy for M&A just FYI.
1 · Reply
Midori_Hachi
Midori_Hachi Mar. 15 at 3:49 PM
$CRBU
0 · Reply
RocroBio
RocroBio Mar. 12 at 7:39 PM
$CRBU
0 · Reply
NicaInvest85
NicaInvest85 Mar. 12 at 12:23 PM
$CRBU markets are in descent but healthcare and biotech will sustain. CRBU target price is around $6-$8 for end of year. The evidence looks promising.
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 10 at 9:36 PM
$CRBU Current Stock Price: $2.04 Contracts to trade: $2.0 CRBU Mar 20 2026 Call Entry: $0.05 Exit: $0.10 ROI: 99% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Mindegap
Mindegap Mar. 10 at 4:23 PM
$MGX $PRME $CRBU
0 · Reply
GamblingFerret
GamblingFerret Mar. 10 at 1:41 PM
$CRBU Recording of Leerink is available. https://event.summitcast.com/view/mT9poctHDNthc6b89WqVjf/guest_book?session_id=oDGi666VY8BTVHda7xriwg They are evaluating both dilutive and non dilutive financing options for Phase 3. Final discussions with FDA on Phase 3 trial ongoing. CB11 partnering ready with availibility of longer term data, dose expansion (ongoing) and regulatory exchange with FDA (ongoing). Very interestingly, autoimmune is in high interest as well, potentially with a partner or alone as IND is in place. So CB10 will expand into autoimmune nearterm.
1 · Reply
Megabyte48
Megabyte48 Mar. 10 at 12:46 AM
$CRBU back to 2.22 tomorrow
1 · Reply
ms82494
ms82494 Mar. 9 at 11:46 PM
$ALLO, $CRBU Very compelling strength from the allogeneic CAR-T stocks, today. Seems like conviction is spreading, as catalysts approach.
0 · Reply
GenomicEquities
GenomicEquities Mar. 9 at 3:54 PM
$CRBU
0 · Reply
NicaInvest85
NicaInvest85 Mar. 9 at 1:19 PM
$CRBU load up this stock is very promising, empirical evidence is showing up.
0 · Reply
3DBuilds
3DBuilds Mar. 9 at 2:45 AM
$BEAM $CRBU $CRSP $EDIT $NTLA
0 · Reply
RocroBio
RocroBio Mar. 7 at 6:20 PM
61.10% return this year across my portfolios. Thank you $CRBU
0 · Reply
Midori_Hachi
Midori_Hachi Mar. 6 at 9:55 AM
$CRBU
0 · Reply
HughGeez
HughGeez Mar. 4 at 11:47 PM
$CRBU In my overly optimistic opinion, the downside risk before a phase 3 clinical trial starts is much, much, much lower then the upside during this time period. I think we get a big pop on the phase 3 announcement and any new partnership. A stock with a phase 3 trial is in a whole different league. Even with these crazy swings, I am holding until at least when phase 3 starts... Hopefully when the price is around $8-$10.
0 · Reply
Jidane
Jidane Mar. 2 at 10:19 PM
$CRBU Let’s see one month later. it’s funny though, who would claim whether it was exit algo or not with 1.1M volume, 2.5mil dollar at most?
1 · Reply
3DBuilds
3DBuilds Mar. 2 at 3:42 PM
$CRSP $NTLA $BEAM $CRBU $EDIT
2 · Reply
Peterson28
Peterson28 Mar. 2 at 3:13 PM
$CRBU Proof that it was exit algo.
0 · Reply